Travere Therapeutics (TVTX) Scheduled to Post Quarterly Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTXGet Rating) will announce its earnings results after the market closes on Thursday, May 5th. Analysts expect the company to announce earnings of ($0.85) per share for the quarter.

Travere Therapeutics (NASDAQ:TVTXGet Rating) last posted its quarterly earnings data on Thursday, February 24th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.12). Travere Therapeutics had a negative return on equity of 55.22% and a negative net margin of 79.16%. The firm had revenue of $57.25 million during the quarter, compared to the consensus estimate of $56.40 million. During the same quarter last year, the company posted ($2.37) EPS. Travere Therapeutics’s revenue for the quarter was up 12.3% compared to the same quarter last year. On average, analysts expect Travere Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of TVTX stock opened at $26.18 on Friday. The company’s fifty day moving average price is $26.77 and its 200-day moving average price is $27.65. The stock has a market cap of $1.66 billion, a PE ratio of -8.51 and a beta of 0.74. The company has a current ratio of 4.70, a quick ratio of 4.64 and a debt-to-equity ratio of 0.75. Travere Therapeutics has a 12 month low of $12.75 and a 12 month high of $31.65.

Several equities research analysts recently commented on the stock. Zacks Investment Research raised shares of Travere Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. HC Wainwright assumed coverage on shares of Travere Therapeutics in a research note on Monday, February 28th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, Piper Sandler started coverage on shares of Travere Therapeutics in a report on Wednesday, March 30th. They issued an “overweight” rating and a $42.00 price objective for the company. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $34.11.

In other news, insider Peter Heerma sold 1,125 shares of the company’s stock in a transaction dated Monday, January 31st. The shares were sold at an average price of $27.40, for a total transaction of $30,825.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Elizabeth E. Reed sold 1,350 shares of the stock in a transaction that occurred on Monday, January 31st. The stock was sold at an average price of $27.40, for a total transaction of $36,990.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,324 shares of company stock valued at $254,767. Company insiders own 4.31% of the company’s stock.

A number of institutional investors have recently made changes to their positions in TVTX. Royal Bank of Canada increased its position in Travere Therapeutics by 132.7% in the second quarter. Royal Bank of Canada now owns 4,053 shares of the company’s stock worth $59,000 after buying an additional 2,311 shares in the last quarter. Amalgamated Bank bought a new position in Travere Therapeutics in the 4th quarter worth approximately $242,000. Schonfeld Strategic Advisors LLC grew its holdings in Travere Therapeutics by 35.1% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 13,100 shares of the company’s stock valued at $407,000 after buying an additional 3,400 shares in the last quarter. Invesco Ltd. raised its position in shares of Travere Therapeutics by 8.4% during the third quarter. Invesco Ltd. now owns 36,972 shares of the company’s stock valued at $897,000 after buying an additional 2,868 shares during the last quarter. Finally, Allianz Asset Management GmbH purchased a new position in shares of Travere Therapeutics in the fourth quarter worth $1,851,000.

About Travere Therapeutics (Get Rating)

Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.

Featured Articles

Earnings History for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.